Virginia Hospital Center Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2007
NCT00599248
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Alternative names

Commonwealth Orthopedics, Virginia Hospital Center

Active Ingredients

Drugs in Phase 2 Trials (1)

allogenic human chondrocytes expressing transforming growth factor-β1 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Joint Diseases (Phase 2)

Osteoarthritis (Phase 2)

Osteoarthritis, Knee (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1